JP2013522302A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522302A5
JP2013522302A5 JP2013500127A JP2013500127A JP2013522302A5 JP 2013522302 A5 JP2013522302 A5 JP 2013522302A5 JP 2013500127 A JP2013500127 A JP 2013500127A JP 2013500127 A JP2013500127 A JP 2013500127A JP 2013522302 A5 JP2013522302 A5 JP 2013522302A5
Authority
JP
Japan
Prior art keywords
yeast
immunotherapy composition
interferon
based immunotherapy
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013500127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522302A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/028359 external-priority patent/WO2011115914A1/en
Publication of JP2013522302A publication Critical patent/JP2013522302A/ja
Publication of JP2013522302A5 publication Critical patent/JP2013522302A5/ja
Withdrawn legal-status Critical Current

Links

JP2013500127A 2010-03-14 2011-03-14 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療 Withdrawn JP2013522302A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US31377510P 2010-03-14 2010-03-14
US31377610P 2010-03-14 2010-03-14
US31377410P 2010-03-14 2010-03-14
US61/313,775 2010-03-14
US61/313,776 2010-03-14
US61/313,774 2010-03-14
US37089910P 2010-08-05 2010-08-05
US61/370,899 2010-08-05
US40785910P 2010-10-28 2010-10-28
US61/407,859 2010-10-28
PCT/US2011/028359 WO2011115914A1 (en) 2010-03-14 2011-03-14 Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy

Publications (2)

Publication Number Publication Date
JP2013522302A JP2013522302A (ja) 2013-06-13
JP2013522302A5 true JP2013522302A5 (enExample) 2014-05-01

Family

ID=44649537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013500127A Withdrawn JP2013522302A (ja) 2010-03-14 2011-03-14 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療

Country Status (4)

Country Link
US (1) US20130121964A1 (enExample)
EP (1) EP2547792A4 (enExample)
JP (1) JP2013522302A (enExample)
WO (1) WO2011115914A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121013B1 (en) 2007-02-02 2014-10-15 Globeimmune, Inc. Methods for producing yeast-based vaccines
CA2681246A1 (en) 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
EP3320915A1 (en) 2009-04-17 2018-05-16 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
PT2534150T (pt) 2010-02-12 2017-05-02 Chimerix Inc Métodos para tratar uma infecção viral
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
US20120196272A1 (en) * 2010-08-05 2012-08-02 Roche Molecular Systems, Inc. Prediction of HCV Viral Kinetics in Interferon-Free Treatment
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP5745102B2 (ja) 2011-02-12 2015-07-08 グローブイミューン，インコーポレイテッド 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
SG193396A1 (en) 2011-03-17 2013-10-30 Globeimmune Inc Yeast-brachyury immunotherapeutic compositions
WO2012174220A1 (en) 2011-06-14 2012-12-20 Globeimmune, Inc. Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
RU2642300C2 (ru) 2011-08-17 2018-01-24 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
SG11201408652SA (en) 2012-06-26 2015-01-29 Biodesix Inc Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
CN104797259A (zh) * 2012-07-03 2015-07-22 奇默里克斯公司 治疗逆转录病毒感染的方法和相关剂量方案
CN102816838A (zh) * 2012-07-06 2012-12-12 吉林艾迪康医学检验所有限公司 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒
KR20150132867A (ko) 2013-03-19 2015-11-26 글로브이뮨 척색종에 대한 효모-기반의 면역치료
TWI626948B (zh) 2013-03-26 2018-06-21 環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
WO2015031778A2 (en) 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
US10799567B2 (en) 2014-04-11 2020-10-13 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
CN107002149A (zh) * 2014-12-18 2017-08-01 豪夫迈·罗氏有限公司 Hbv治疗应答的生物标志物
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
KR20170102002A (ko) 2015-01-09 2017-09-06 이투빅스 코포레이션 에볼라 바이러스 백신접종을 위한 방법 및 조성물
JP6738319B2 (ja) * 2015-03-30 2020-08-12 雅史 溝上 インターフェロン治療効果予測方法及びそれを用いたｂ型肝炎患者の治療用医薬組成物
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
CN107787372A (zh) * 2015-07-15 2018-03-09 豪夫迈·罗氏有限公司 Hbv 治疗应答的生物标志物
JP6789283B2 (ja) 2015-08-03 2020-11-25 グローブイミューン，インコーポレイテッド 改変酵母−ブラキュリー免疫療法組成物
RU2623151C2 (ru) * 2015-11-03 2017-06-22 Федеральное государственное казенное учреждение Главный клинический военный госпиталь ФСБ России Способ прогнозирования динамики фиброза печени у пациентов с хроническим гепатитом С, генотипом 1, не ответивших на лечение пегилированными интерферонами и рибавирином
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN112543640B (zh) 2018-05-15 2025-02-14 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
JP7417339B1 (ja) 2023-08-07 2024-01-18 シンバイオ製薬株式会社 アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP2460533A3 (en) * 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20100034840A1 (en) * 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
CA2761125A1 (en) * 2009-05-21 2010-11-25 Schering Corporation Genetic markers associated with interferon-alpha response
US20100316608A1 (en) * 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition

Similar Documents

Publication Publication Date Title
JP6668468B2 (ja) Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法
Sherman et al. Entecavir therapy for lamivudine‐refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks
JP2012513479A5 (enExample)
Brunetto et al. Interferon therapy of chronic hepatitis B
JP2016531144A5 (enExample)
JP2018531272A6 (ja) Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法
JP2012519181A5 (enExample)
Mallet et al. The impact of human immunodeficiency virus on viral hepatitis
JP2015517528A5 (enExample)
JP2012503011A5 (ja) 慢性ｃ型肝炎ウイルス感染症のための酵母系免疫治療組成物
RU2015114543A (ru) Способы лечения гепатита с
JP2014504643A5 (enExample)
JP2015528449A5 (enExample)
JP2013529627A5 (enExample)
RU2012136824A (ru) Способы лечения вирусной инфекции гепатита с
JP2019505553A5 (enExample)
RU2015114566A (ru) Способы лечения гепатита с
CN102083435A (zh) 特拉匹韦给药方案
Marcellin et al. CONTINUED EFFICACY AND SAFETY THROUGH 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102): PRELIMINARY ANALYSIS: 476
Takkenberg et al. New developments in antiviral therapy for chronic hepatitis B
Chen et al. The current status of combination therapy of chronic hepatitis B.
Sokal et al. Chapter 6.1. Pediatric chronic hepatitis B and C: 30 years of ESPGHAN clinical research and recommendations
Mahtab et al. REP 9AC': A second generation HBsAg release inhibitor with improved tolerability: 424
Papatheodoridis et al. CHANGES OF SERUM HBSAG LEVELS IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS UNDER LONGTERM THERAPY WITH NUCLEOS (T) IDE ANALOGUE (S): 1458
Park et al. A PROSPECTIVE RANDOMIZED TRIAL OF SWITCHING TO TELBIVUDINE PLUS ADEFOVIR IN PATIENTS WITH HBEAG-POSITIVE LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B WHO HAVE A SUBOPTIMAL RESPONSE TO LAMIVUDINE PLUS ADEFOVIR: INTERIM ANALYSIS AT 24 WEEKS: 1459